Premier Biomedical Inc (OTCMKTS:BIEI) is moving up steadily on fast accelerating volume off the base it formed in recent month at the $0.01 level.
The stock saw a big move late last year after the Company’s insistence they may have a cure for cancer coupled with significant insider buying. According to CEO William A. Hartman ”I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis.”
Premier Biomedical Inc (OTCMKTS:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent.
Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.
Premier Biomedical, Inc. is developing a methodology for treating multiple diseases, such as cancer, which is completely different from the standard treatments now being utilized. The vast majority of presently known treatments directly inject possibly harmful agents into the body of a patient. This presents a very real risk of adverse side effects from the treatment.
BIEI proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects. We believe this method could be superior to current treatments which counteract symptoms or eliminate the presence of most illnesses, but often are accompanied by catastrophic or even fatal side effects. Premier’s “Subtractive” therapy is designed to eliminate the etiology agent(s) or modify the pathophysiological changes brought about by certain diseases, thereby reducing risks associated with conventional “Additive” therapy (i.e., adding chemicals to the body).
The initial disease target is breast cancer, however, we believe this same methodology can also be applied in the future to treating other forms of cancer, Leukemia, Muscular Dystrophy, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia, and Atherosclerosis. Collectively, these diseases represent over $700 billion in annual treatment costs today. This is a tremendous market opportunity for Premier’s methodology, and, many of these diseases can be orphan drug designated (regulatory fast track).
Premier has developed a proprietary patented drug candidate, Feldetrex™. Based on our initial studies, we found Feldetrex™ to be another promising option for the comprehensive management of muscular and neuropathic pain, as well as chemical addiction. This unique drug combination is expected to deliver significant relief to patients, while presenting fewer, if any, side effects than alternate medications currently available. The annual market size for all proposed market segments for Feldetrex™ is over $20 Billion. The company strategy is to use the sales of Feldetrex™ to provide short term revenue and to fund our continuing technology development efforts.
To Find out the inside Scoop on BIEI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
BIEI has been putting out some big press lately starting in October when they announced the signing of a non-binding Letter of Intent (LOI) with Auramedi Farmacêutica Ltda (a Brazilian pharmaceutical company) to enter into discussions to explore forming a possible Joint Venture (JV) in Brazil to develop Premier’s various treatment technologies, and oversee the manufacture and distribution of the drugs and devices in the South American market initially.
The formation of this joint venture is expected to expedite the approval, manufacture, sales and distribution of Premier’s proprietary treatments. A third party has projected annual sales, in South America, for Premier’s treatments at $400M by the year 2020.
On August 22 BIEI announced the appointment of Dr. Patricio F. Reyes to its Board of Directors and to the position of Chief Technical Officer (CTO) effective immediately. He will report to Premier’s President and CEO, William A. Hartman. As Chief Technical Officer, Dr. Reyes fills the vacancy recently created by the untimely passing of Dr. James Frincke. Our condolences go out the family of Dr. Frincke.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $1.7 million market valuation BIEI has minimal assets, no revenues to date and fast rising debt that has led to massive dilution in the past and likely will again in the future. BIEI is focused on developing medical treatments for diseases in humans especially the hunt for a cure for cancer where they say they have been making great strides with CEO William A. Hartman stating ”I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis.” after they obtained exclusive rights to the recently allowed U.S. patent application, “Sequential Extracorporeal Treatment of Bodily Fluids” I would take this statement with a huge grain of salt; really huge gain of salt. We will be updating on BIEI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEI.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in BIEI either long or short and we have not been compensated for this article.